Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-012194
Filing Date
2022-08-04
Accepted
2022-08-04 16:12:46
Documents
68
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rain-20220630x10q.htm   iXBRL 10-Q 1542604
2 EX-10.2 rain-20220630xex10d2.htm EX-10.2 68102
3 EX-10.3 rain-20220630xex10d3.htm EX-10.3 54861
4 EX-10.4 rain-20220630xex10d4.htm EX-10.4 48491
5 EX-31.1 rain-20220630xex31d1.htm EX-31.1 12836
6 EX-31.2 rain-20220630xex31d2.htm EX-31.2 16742
7 EX-32.1 rain-20220630xex32d1.htm EX-32.1 12809
8 GRAPHIC rain-20220630x10q007.jpg GRAPHIC 52846
  Complete submission text file 0001558370-22-012194.txt   7283566

Data Files

Seq Description Document Type Size
9 EX-101.SCH rain-20220630.xsd EX-101.SCH 54199
10 EX-101.CAL rain-20220630_cal.xml EX-101.CAL 48167
11 EX-101.DEF rain-20220630_def.xml EX-101.DEF 180571
12 EX-101.LAB rain-20220630_lab.xml EX-101.LAB 485321
13 EX-101.PRE rain-20220630_pre.xml EX-101.PRE 333157
62 EXTRACTED XBRL INSTANCE DOCUMENT rain-20220630x10q_htm.xml XML 1264204
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Therapeutics Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40356 | Film No.: 221136705
SIC: 2834 Pharmaceutical Preparations